لوكسمبورغ - الأربعاء, 15. يوليو 2026 أيتوس واير
(BUSINESS WIRE)-- وقّعت شركة Samsung Electronics اتفاقية للانضمام إلى مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع كأحد الحاصلين على التراخيص، لتصبح في الوقت نفسه جهة مانحة لحقوق الترخيص ضمن هذا البرنامج.
ويمثل هذا القرار الصادر عن الشركة الك…
Chughtai Clinic opens Decoded MenoMind, an integrated menopause programme in Dubai
New service at Dubai Healthcare City brings symptom management and long-term health into one pathway — and brings partners into the conversation.
Menopause care in the UAE has long been fragmented: a woman navi…
LUXEMBOURG - Tuesday, 14. July 2026 AETOSWire
(BUSINESS WIRE)--Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme.
The decision by the South Korean company - a global R&D powerhouse and among the world’s top sm…
Highlights:
LTTS joins the Claude Partner Network, integrates Claude models across its Engineering Intelligence platforms, including AgenticIQ, PlxAI, Ainfonix™, AiNexus and AiTest
Claude used by LTTS to help its enterprise clients transform engineering workflows, accelerate innovation and unloc…
يعكس هذا المزيج الفريد من التكنولوجيا 25 عامًا من الابتكار والخبرة في هذا المجال، وفتح أبواب المرحلة التالية من نمو أعمال الشركة وقيمة عملائها
(BUSINESS WIRE)-- اليوم، أعلنت Real Chemistry، وهي الشركة الرائدة عالميًا في مجال الرؤى القائمة على الذكاء الاصطناعي والتسويق والاتصالات حصريًا لقطاع…
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value
(BUSINESS WIRE)--Real Chemistry, a global leader in AI-driven insights and marketing and communications exclusively for the healthcar…
(BUSINESS WIRE)-- يسرُّ Record Asset Management GmbH (RAM)، إحدى الشركات التابعة لـ Record plc (Record Financial Group) المسجلة في لندن، أن تعلن عن إطلاق Record Amanah، وهي منصتها المخصصة للحلول الاستثمارية المتوافقة مع الشريعة.
RAM هي فرع إدارة الأصول الأوروبي من Record Financial Group، أي ا…
SAN FRANCISCO - Tuesday, 14. July 2026 AETOSWire
(BUSINESS WIRE)--Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services.
Founded in 2008 and headquartered in Turkey, ODS Consu…
SANTA MONICA, Calif. - Tuesday, 14. July 2026 AETOSWire Print
Partnership combines the Databricks platform with West Monroe's implementation expertise to help Clearlake build an “investment firm of the future” data platform across deal origination, due diligence, fund operations, and portfolio c…
لوكسمبورغ - الأربعاء, 15. يوليو 2026 أيتوس واير
(BUSINESS WIRE)-- وقّعت شركة Samsung Electronics اتفاقية للانضمام إلى مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع كأحد الحاصلين على التراخيص، لتصبح في الوقت نفسه جهة مانحة لحقوق الترخيص ضمن هذا البرنامج.
ويمثل هذا القرار الصادر عن الشركة الك…
Chughtai Clinic opens Decoded MenoMind, an integrated menopause programme in Dubai
New service at Dubai Healthcare City brings symptom management and long-term health into one pathway — and brings partners into the conversation.
Menopause care in the UAE has long been fragmented: a woman navi…
LUXEMBOURG - Tuesday, 14. July 2026 AETOSWire
(BUSINESS WIRE)--Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme.
The decision by the South Korean company - a global R&D powerhouse and among the world’s top sm…
Highlights:
LTTS joins the Claude Partner Network, integrates Claude models across its Engineering Intelligence platforms, including AgenticIQ, PlxAI, Ainfonix™, AiNexus and AiTest
Claude used by LTTS to help its enterprise clients transform engineering workflows, accelerate innovation and unloc…
يعكس هذا المزيج الفريد من التكنولوجيا 25 عامًا من الابتكار والخبرة في هذا المجال، وفتح أبواب المرحلة التالية من نمو أعمال الشركة وقيمة عملائها
(BUSINESS WIRE)-- اليوم، أعلنت Real Chemistry، وهي الشركة الرائدة عالميًا في مجال الرؤى القائمة على الذكاء الاصطناعي والتسويق والاتصالات حصريًا لقطاع…
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value
(BUSINESS WIRE)--Real Chemistry, a global leader in AI-driven insights and marketing and communications exclusively for the healthcar…
(BUSINESS WIRE)-- يسرُّ Record Asset Management GmbH (RAM)، إحدى الشركات التابعة لـ Record plc (Record Financial Group) المسجلة في لندن، أن تعلن عن إطلاق Record Amanah، وهي منصتها المخصصة للحلول الاستثمارية المتوافقة مع الشريعة.
RAM هي فرع إدارة الأصول الأوروبي من Record Financial Group، أي ا…
SAN FRANCISCO - Tuesday, 14. July 2026 AETOSWire
(BUSINESS WIRE)--Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services.
Founded in 2008 and headquartered in Turkey, ODS Consu…
SANTA MONICA, Calif. - Tuesday, 14. July 2026 AETOSWire Print
Partnership combines the Databricks platform with West Monroe's implementation expertise to help Clearlake build an “investment firm of the future” data platform across deal origination, due diligence, fund operations, and portfolio c…
لوكسمبورغ - الأربعاء, 15. يوليو 2026 أيتوس واير
(BUSINESS WIRE)-- وقّعت شركة Samsung Electronics اتفاقية للانضمام إلى مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع كأحد الحاصلين على التراخيص، لتصبح في الوقت نفسه جهة مانحة لحقوق الترخيص ضمن هذا البرنامج.
ويمثل هذا القرار الصادر عن الشركة الكورية الجنوبية - إحدى أبرز القوى العالمية في مجال البحث والتطوير، ومن بين الشركات الرائدة عالميًا في سوق الهواتف الذكية، إضافة إلى ريادتها في عدد من فئات المنتجات الإلكترونية الأخرى - تأكيدًا جديدًا على مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع كحل موثوق للجهات التي تتطلع إلى تقليل المخاطر المرتبطة بتطبيق تقنيات Wi-Fi. كما يعزّز هذا الانضمام بصورة كبيرة نطاق محفظة براءات الاختراع المتاحة ضمن البرنامج.
ومنذ الإعلان عن إطلاقها رسميًا في يناير 2026، نجح مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع في استقطاب عدد من الشركات العالمية الرائدة، حيث أصبحت كل من ASUS، وHewlett Packard Enterprise، وMicrosoft، وSony Group Corporation من الجهات المرخَّص لها بموجب البرنامج. كما يضم المجمّع أيضًا خمس شركات تجمع بين صفة مانح الترخيص والحاصل على الترخيص: Huawei، وPanasonic، وPhilips، وSamsung Electronics، وZTE. أما الجهات الأخرى المانحة للتراخيص فتشمل: KPN، وMitsubishi Electric، وOrange، وAegis 11 SA، وSK Telecom، وWilus.
وتضع الاتفاقية التي أُعلن عنها اليوم حدًا للإجراءات القضائية بين Samsung Electronics وWilus أمام المحكمة الجزئية الأمريكية للمنطقة الشرقية من تكساس.
يغطي مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع براءات الاختراع الأساسية للمعايير الخاصة بكل من Wi-Fi 6 وWi-Fi 7، ويوفّر وسيلة فعّالة للحصول على حقوق الملكية الأساسية لتقنيات Wi-Fi على المدى الطويل. يُعدّ الجيل اللاحق لمجمّع براءات الاختراع الخاص بتقنية Wi-Fi 6 التابع لشركة Sisvel. وعلى مدار ثلاث سنوات من هذا البرنامج، تم إبرام اتفاقيات ترخيص مع 40 شركة، بما في ذلك Acer وNetgear وCisco وHP.
وقال Nick Webb، الرئيس التنفيذي لقطاع التراخيص في Sisvel: "يمثل انضمام Samsung Electronics إلى مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع بصفتها جهة مانحة للتراخيص وحاصلة عليها في الوقت نفسه، محطة بارزة ومهمة في مسيرة المجمّع". "لقد أثبت حل مجموعة التراخيص، مرة أخرى، أنه وسيلة فعّالة للحد من النزاعات المتعلقة ببراءات اختراع Wi-Fi وتسويتها. وعلاوة على ذلك، أصبح هذا الحل الآن خيارًا أكثر جاذبية للترخيص أمام الجهات المبتكرة في مجال تقنيات Wi-Fi".
وقال Heath Hoglund، الرئيس التنفيذي لشؤون الملكية الفكرية في Sisvel: "يسرُّنا انضمام Samsung Electronics إلى المجمّع بصفتها جهة حاصلة على الترخيص ومانحة له في الوقت نفسه". "وبفضل حجم Samsung وانتشارها العالمي، يمثل هذا انطلاقةً مهمة لتأكيد مكانة البرنامج وتعزيز مصداقيته عبر فئات متعددة من المنتجات. "يوفر مجمّع Sisvel لتقنيات Wi-Fi متعددة الأوضاع مزيدًا من الوضوح في مجال التراخيص للجهات المطوِّرة والمطبِّقة للتقنيات عبر مختلف القطاعات، كما تمثل الخيار الأكثر كفاءة لأصحاب براءات الاختراع في هذا المجال".
نبذة عن شركة Sisvel
يحكم عمل شركة Sisvel اعتقادها بأهمية التعاون والإبداع والكفاءة لتلبية احتياجات أصحاب براءات الاختراع وأولئك الذين يرغبون في الاستفادة من تقنياتهم. وفي ظل التعامل مع سوق معقدة ومتطورة باستمرار، يهدف المبدأ التوجيهي لدينا في خلق فرص متكافئة من خلال تطوير حلول تسويقية مرنة وبسيطة وتنفيذها.
Sisvel | We Power Innovation
إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.
الرابط الثابت
https://www.aetoswire.com/ar/news/1507202656285
جهات الاتصال
الإعلام
Giulia Dini
Executive Head of Brand
الهاتف: +34 93 131 5570
giulia.dini@sisvel.com
Chughtai Clinic opens Decoded MenoMind, an integrated menopause programme in Dubai
New service at Dubai Healthcare City brings symptom management and long-term health into one pathway — and brings partners into the conversation.
Menopause care in the UAE has long been fragmented: a woman navigating hot flushes, brain fog and shifting cardiovascular risk might see three or four specialists who never speak to each other. Chughtai Clinic is betting women want it handled in one place.
The Dubai Healthcare City polyclinic, licensed by the Dubai Health Authority, has launched Decoded MenoMind, an integrated menopause care and bio-intelligence programme for women in perimenopause, menopause and post-menopause. It combines hormonal and psychological care, nutrition, physical strength work and lifestyle support into one coordinated pathway — and, notably for the region, extends guidance to partners supporting women through the transition.
The clinical logic is straightforward: menopause affects physical strength, cardiovascular, bone and cognitive health, yet these are typically assessed separately, delaying diagnosis. Decoded MenoMind manages them together, focused on healthspan rather than lifespan alone. The programme covers six areas — hormonal assessment, cognitive and mental health, clinical nutrition, cardiovascular/bone/brain health, physical wellness, and emotional and lifestyle support — beginning with assessment and diagnostics, then a personalized plan with coordinated follow-up.
"Women often consult several specialists independently, which can delay care," said Dr. Omar Chughtai, CEO. COO Monu Choudhary added that patients now "move through assessment, diagnostics and follow-up as one continuous process," involving partners "because this transition affects the whole household."
Mental health is built into the pathway from the start. "Changes in mood, sleep and concentration are among the most common symptoms — and the least discussed," said Dr. Balu Pitchiah, Consultant Psychiatrist and MenoMind co-founder.
Decoded MenoMind is open now at Chughtai Clinic, Dubai Healthcare City. Appointments: +971 55 981 1068, management@chughtaiclinic.ae, or chughtaiclinic.ae/decodedmenomind.
About Chughtai Clinic
Units 102–105, Building 47 (Al Jazari), Dubai Healthcare City. For more information, visit https://chughtaiclinic.ae/
Permalink
https://aetoswire.com/en/news/chc14072026e
Contacts
ALEENA JOYS,
PR Manager
management@chughtaiclinic.ae
+971 55 981 1068
Not intended for Canada-, UK- or US-based media
(BUSINESS WIRE) -- Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination with FOLFOX (BREAKWATER regimen) and for patients who have received prior systemic therapy (BEACON regimen).
The first-line approval is based on results from the Phase 3 BREAKWATER trial, which showed that the cetuximab–encorafenib–FOLFOX combination delivered statistically significant and clinically meaningful improvements in the dual primary endpoints of objective response rate (ORR) and PFS, as well as a significant overall survival benefit — reducing the risk of death by 51% versus chemotherapy with or without bevacizumab.
”The approval of Erbitux in combination with encorafenib and FOLFOX marks an important milestone for patients with BRAF V600E-mutant mCRC who can now benefit from a first targeted treatment option in the first-line setting,” said Matthias Wernicke, Head of Global Therapeutic Area Specialty Care, in the healthcare business sector of Merck. “BRAF V600E-mutant mCRC is associated with a historically poor prognosis and limited effective options. This approval reinforces Erbitux as the backbone of anti-EGFR therapy in colorectal cancer — and reflects our ongoing commitment to addressing unmet needs for patients across the full treatment continuum.”
BREAKWATER (NCT04607421) is a Phase 3, randomized, active-controlled, open-label, multicenter trial evaluating encorafenib in combination with cetuximab and FOLFOX in participants with previously untreated BRAF V600E-mutant mCRC. The trial was conducted by Pfizer, in collaboration with Merck, and Ono Pharmaceutical. The combination of cetuximab, encorafenib and FOLFOX received accelerated FDA approval in December 2024 for treatment-naïve patients based on ORR data, and full FDA approval in February 2026 based on PFS and OS data — with the indication expanded to include fluorouracil-based chemotherapy (FOLFOX or FOLFIRI).
The BREAKWATER regimen demonstrated statistically significant and clinically meaningful improvements across all key endpoints versus standard-of-care chemotherapy (FOLFOX/FOLFOXIRI/CAPOX with or without bevacizumab).1,2 Median PFS was 12.8 months versus 7.1 months (HR 0.53; 95% CI: 0.41–0.68; P<0.001), representing a 47% reduction in the risk of progression or death. Overall survival was likewise significantly improved, with a median OS of 30.3 months versus 15.1 months (HR 0.49; 95% CI: 0.38–0.63; P<0.001) — a 51% reduction in the risk of death, more than doubling median overall survival compared to standard care. Confirmed ORR was 65.7% (95% CI: 59.4–71.4) in the BREAKWATER arm versus 37.4% (95% CI: 31.6–43.7) in the control arm. Safety profiles were consistent with those previously established for each individual agent; serious adverse events occurred in 46.1% versus 38.9% in the standard-care arm.
The cetuximab–encorafenib–FOLFOX regimen has been endorsed as first-line standard of care by the April 2026 ESMO Clinical Practice Guidelines (Recommendation Grade I, A) for patients with metastatic colorectal cancer harboring the BRAF V600E mutation.3
While the BREAKWATER regimen redefines first-line therapy, the Phase 3 BEACON CRC trial confirmed Erbitux as a standard of care in second-line and beyond. The combination of Erbitux and encorafenib — also approved by the EC on June 26, 2026 for patients with BRAF V600E-mutant mCRC who have received prior systemic therapy — significantly improved OS versus the irinotecan-based control (median 9.3 vs. 5.9 months; HR 0.61; 95% CI: 0.48–0.77; p<0.0001), reducing the risk of death by 39%.4,5 This regimen maintains quality of life with no increase in Grade ≥3 adverse events versus standard chemotherapy.
Erbitux is the first and only anti-EGFR therapy approved for both RAS wild-type and BRAF V600E-mutant mCRC patients — supporting patients throughout their treatment journey and across multiple lines of therapy.
Colorectal cancer remains a major global health challenge. It is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related deaths, with 1.92 million new cases and approximately 900,000 deaths recorded in 2022 alone.6 Projections indicate cases will increase by more than 85% and mortality will double in coming decades. Of patients presenting with metastatic disease — approximately 20% at diagnosis — 5-year survival remains at only 16.2%.
BRAF V600E mutations occur in approximately 8–12% of patients with mCRC and are associated with a particularly poor prognosis, with mortality risk more than double that of patients without the mutation. Extending the indication of Erbitux to this patient population represents a meaningful step toward more personalized and effective treatment — addressing a significant and clinically important unmet need.
With this dual approval — first-line (BREAKWATER) and second-line (BEACON) — Erbitux is now established as the pioneering anti-EGFR backbone across the mCRC treatment continuum. This milestone underscores Merck’s commitment to driving innovation in oncology and improving outcomes for patients with difficult-to-treat cancers.
Local HCP Declaration
Pierre Fabre, which holds the commercialization rights for BRAFTOVI (encorafenib) in Europe, submitted the BREAKWATER data to European Medical Agency (EMA) and received EC approval on June 22,2026. The BEACON regimen was already approved under BRAFTOVI since June 2020.
About BREAKWATER Study
BREAKWATER is a Phase 3, randomized, open-label, multicenter trial, whose findings support a targeted, first-line approach for patients with BRAF V600E-mutant mCRC.2 The combination of ERBITUX, encorafenib, and the FOLFOX regimen significantly improved outcomes versus standard of care, with a 47% reduction in the risk of progression or death (HR 0.53) and a 51% reduction in the risk of death (HR 0.49). The data also show a meaningful increase in the ORR and a median OS of over 30 months in the experimental arm, underscoring the value of combined inhibition of BRAF and EGFR pathways in this poor-prognosis population and suggesting this treatment strategy as a new first-line standard of care.
About BEACON Study
BEACON CRC is a randomised, open-label, global Phase 3 trial evaluating the efficacy and safety of ERBITUX in combination with encorafenib ± binimetinib in patients with BRAF V600E-mutant mCRC whose disease has progressed after one or two prior regimens. BEACON CRC is the first Phase 3 trial designed to test a BRAF combination targeted therapy in BRAF V600E-mutant mCRC.
The data showed that ERBITUX in combination with encorafenib significantly improved OS in patients with BRAF V600E-mutant mCRC (median 9.3 months vs 5.9 months; HR: 0.61; 95% CI: 0.48–0.77; p<0.0001) and reduced the risk of death by 39%, compared with the ERBITUX plus irinotecan-containing regimen (control) arm. Data also showed that, besides improving OS, ERBITUX-encorafenib resulted in no worsening in quality of life or increase in grade 3 AEs versus irinotecan-based chemotherapy–cetuximab.4,5
About Cetuximab (ERBITUX®)
Cetuximab is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Cetuximab is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, Cetuximab also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody-dependent cell-mediated cytotoxicity [ADCC]).
Cetuximab has already obtained market authorization in over 100 countries worldwide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck. Merck licensed the right to market ERBITUX (Cetuximab), a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company, in 1998.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
_____________________
1 Elez E, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N Engl J Med. 2025;392:2425–37.
2 Kopetz S, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med. 2025;31:901–908.
3 Cremolini C, et al. on behalf of the ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026. doi: https://doi.org/10.1016/j.annonc.2026.03.005.
4 Kopetz S, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019. PMID: 31566309.
5 Tabernero J, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273–284.
6 World Health Organization. Colorectal cancer: Key facts. Accessed 14 July 2026. https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260714604485/en/
Permalink
https://www.aetoswire.com/en/news/1407202656247
Contacts
Sebastian Roos
sebastian.roos@merckgroup.com
Phone: +49 151 14 54 1721
LUXEMBOURG - Tuesday, 14. July 2026 AETOSWire
(BUSINESS WIRE)--Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme.
The decision by the South Korean company - a global R&D powerhouse and among the world’s top smartphone vendors, as well as a leader in many other electronic product categories - not only confirms the Sisvel Wi-Fi Multimode pool as a recognised solution provider for parties seeking to derisk Wi-Fi implementation but also considerably expands the scope of the programme’s patent offering.
Since it was publicly launched in January 2026, ASUS, Hewlett Packard Enterprise, Microsoft and Sony Group Corporation have become licensees of the Sisvel Wi-Fi Multimode pool. There are also five licensor/licensee companies: Huawei, Panasonic, Philips, Samsung Electronics and ZTE. The other licensors are KPN, Mitsubishi Electric, Orange, Aegis 11 SA, SK Telecom and Wilus.
The agreement announced today ends litigation in the Eastern District of Texas between Samsung Electronics and Wilus.
The Sisvel Wi-Fi Multimode pool covers both Wi-Fi 6 and Wi-Fi 7 standard essential patents and offers an efficient way to access essential Wi-Fi rights for years to come. It is the successor to the Sisvel Wi-Fi 6 patent pool. Over a three-year period under that programme, agreements were closed with 40 companies, including Acer, Netgear, Cisco and HP.
“Having Samsung Electronics join as a licensor and licensee is a major milestone for the Sisvel Wi-Fi Multimode pool,” says Nick Webb, Sisvel’s Executive Head of Licensing. “Once again, the pool solution has shown itself to be an effective way to prevent and solve Wi-Fi-related patent disputes. More than that, though, it is now an even more attractive licensing option for Wi-Fi innovators.”
“It is exciting to have Samsung Electronics join the pool as both a licensee and licensor,” says Sisvel Chief IP Officer Heath Hoglund. “Because of Samsung’s size and reach, this represents a significant validation of the programme in multiple product categories. Sisvel Wi-Fi MM is providing ever-greater licensing clarity to implementers across all verticals and the most efficient licensing choice for patent owners in the space.”
About Sisvel
Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field through the development and implementation of flexible, accessible, commercialisation solutions.
Sisvel | We Power Innovation
View source version on businesswire.com: https://www.businesswire.com/news/home/20260713601810/en/
Permalink
https://www.aetoswire.com/en/news/1407202656246
Contacts
Media
Giulia Dini
Executive Head of Brand
Tel: +34 93 131 5570
giulia.dini@sisvel.com
Highlights:
LTTS joins the Claude Partner Network, integrates Claude models across its Engineering Intelligence platforms, including AgenticIQ, PlxAI, Ainfonix™, AiNexus and AiTest
Claude used by LTTS to help its enterprise clients transform engineering workflows, accelerate innovation and unlock new revenue opportunities
(BUSINESS WIRE)--L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced a partnership with Anthropic to accelerate Engineering Intelligence by integrating Claude models across engineering processes and LTTS’ AI-powered platforms. The collaboration will help LTTS’ enterprise clients redesign how products and software are developed, enabling faster innovation and improved outcomes at scale.
Leveraging Claude across the engineering lifecycle and uniting deep engineering expertise, advanced AI and domain knowledge, LTTS’ Engineering Intelligence discipline will enable clients to create greater value. Rather than automating individual tasks, it enables teams to make faster decisions, streamline workflows and continuously improve how products, manufacturing plants and industrial systems are designed, built and maintained.
By integrating Claude models into its platforms including AgenticIQ, PlxAI, Ainfonix™, AiNexus and AiTest, LTTS will accelerate engineering across the product and software development lifecycle. The integration of Claude spans knowledge management, software development, validation, testing and lifecycle management, enabling clients to improve quality, productivity and speed to market.
“Engineering is entering a new era where intelligence is becoming an integral part of how products are designed, software is developed and engineering decisions are made,” said Amit Chadha, CEO & Managing Director, L&T Technology Services. “At LTTS, our vision of Engineering Intelligence is about fundamentally redesigning engineering work, not simply automating existing processes. Our partnership with Anthropic represents a significant step in that journey, enabling us to embed Claude into engineering workflows and accelerate innovation for our global clients.”
About L&T Technology Services Ltd
L&T Technology Services (LTTS) is a global leader in Engineering Intelligence Solutions & ER&D Consulting Services. A listed subsidiary of Larsen & Toubro (L&T), we offer design, development, testing, and sustenance services across products and processes. Purposeful. Agile. Innovation. is how we drive growth across the Mobility, Sustainability and Tech segments. Our client base includes 69 Fortune 500 companies and 57 top ER&D companies across industrial products, medical devices, transportation, telecom & hi-tech, and process industries. Headquartered in India, we have over 23,840 employees across 21 global design centers, 30 global sales offices, and 103 innovation labs, as of June 30, 2026.
For additional information about L&T Technology Services log on to https://www.ltts.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260714127801/en/
Permalink
https://www.aetoswire.com/en/news/1407202656266
Contacts
Media Contact:
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.Basu@LTTS.com
Sayanti Chakraborty
L&T Technology Services Limited
E: Sayanti.Chakraborty@LTTS.com
يعكس هذا المزيج الفريد من التكنولوجيا 25 عامًا من الابتكار والخبرة في هذا المجال، وفتح أبواب المرحلة التالية من نمو أعمال الشركة وقيمة عملائها
(BUSINESS WIRE)-- اليوم، أعلنت Real Chemistry، وهي الشركة الرائدة عالميًا في مجال الرؤى القائمة على الذكاء الاصطناعي والتسويق والاتصالات حصريًا لقطاعي الرعاية الصحية وعلوم الحياة، عن إطلاق Real Chemistry ANATOMI، وهو نظام بيئي لحلول الذكاء الاصطناعي مصمم خصوصًا لدعم دورة التسويق الكاملة للرعاية الصحية. ويتزامن هذا الإطلاق مع الذكرى السنوية الخامسة والعشرين لإنشاء شركة Real Chemistry، ويأتي كعلامة فارقة في تطورها المستمر والتزامها بالتلبية المتواصلة لاحتياجات العملاء في سوق سريعة التغير.
تم بناء Real Chemistry ANATOMI على أساس من البيانات المتقدمة الخاصة والبيانات الخارجية، والنماذج اللغوية الكبيرة (LLMs) ومنصات التنسيق، وهي تدمج الذكاء الاصطناعي في مجالات التسويق والشؤون الطبية والاتصالات وسير العمل الإعلامي. لقد تم تصميم النظام البيئي لتمكين خبراء Real Chemistry وعملائها بحلول الذكاء الاصطناعي المتصلة والقابلة للتطوير والمخصصة للرعاية الصحية والتي تؤدي إلى نتائج قابلة للقياس، بدءًا من توليد الأفكار وإنشاء الاستراتيجية، مرورًا بالتطوير الإبداعي والتفعيل متعدد القنوات.
وعن ذلك، قال Shankar Narayanan، الرئيس التنفيذي لشركة Real Chemistry: "يمثل برنامج Real Chemistry ANATOMI نهجنا القائم على القيم والأولوية للأفراد في مجال الذكاء الاصطناعي. وعلى مدار 25 عامًا، تطورنا واستثمرنا في المواهب والبيانات والتكنولوجيا اللازمة لمساعدة العملاء في تلبية احتياجات السوق المتزايدة التعقيد. وتجمع منصة Real Chemistry ANATOMI بين هذه المزايا معًا في نظام بيئي متكامل للذكاء الاصطناعي يساعد فرقنا في العمل بذكاء أكبر، والتصرُّف بشكل أسرع، وتقديم نتائج أكثر جدوى للعملاء ومقدمي الخدمات والمرضى."
يقدم نظام Real Chemistry ANATOMI البيئي حلولاً خاصة بالرعاية الصحية مصممة خصوصًا لتناسب التعقيد التنظيمي والفروق الدقيقة العلاجية وديناميكيات السوق الواقعية التي تشكل رحلة التسويق، مع استيعاب جميع البيانات المصرح بها وتخزينها بطريقة محكمة ومتوافقة للغاية. وتجمع المنصة Real Chemistry ANATOMI بين أدوات التحليل والأدوات الوكيلة لدعم الاحتياجات الخاصة بسير العمل لتحسين الجودة وتسريع عملية صنع القرار وتمكين تنفيذ أكثر ترابطًا واتساقًا على نطاق واسع.
ولقد تم تطوير أدواتها الفعّالة من خلال التكرار المدروس والتحقق من صحتها في العالم الحقيقي، وهي تدعم بالفعل سير العمل الأساسي لتسويق الرعاية الصحية:
Real Chemistry ANATOMI Communications، وهي مجموعة منتقاة ومخصصة لسير عمل الاتصالات في مجال الرعاية الصحية، بما في ذلك تحليل اتجاهات السوق، وإعداد التقارير عن النشاط الإعلامي، وإحاطة الصحفيين، وتخطيط وتنفيذ اتصالات المديرين التنفيذيين
أدوات لدعم سير العمل الإعلاني والتسويقي الشامل، بدءًا من تطوير استراتيجية العلامة التجارية إلى استكشاف الاتجاهات الثقافية، ومن إنشاء المحتوى إلى تقييم المخاطر بهدف الامتثال لهيئة الغذاء والدواء الأمريكية (FDA)
مجموعة أدوات مصممة خصوصًا لتسريع الوصول إلى المعلومات وتحقيق الجودة في التواصل الطبي، بما في ذلك Real Chemistry ANATOMI Publications - وهي منصة متكاملة مدعومة بالذكاء الاصطناعي لتخطيط وتنفيذ المنشورات العلمية
الجيل التالي من منصة HealthGEO التابعة لشركة Real Chemistry - أول منصة ذكاء جغرافي متخصصة في مجال الرعاية الصحية في هذا القطاع
يمثل إطلاق Real Chemistry ANATOMI المرحلة التالية من استثمار الشركة طويل الأمد في البيانات والتكنولوجيا والخبرة المتخصصة في مجال الرعاية الصحية، ويعزز استراتيجيتها لقيادة الصناعة في التحول المدعوم بالذكاء الاصطناعي.
ومع تسارع وتيرة الابتكار في شتى جوانب المجال، يستمر تركيزReal Chemistry على إمشاء حلول تزيد من مساحة الإبداع البشري، وتربط سير العمل وتيسر تحوله، وتساعد العملاء في تحقيق نتائج عملية وصحية أقوى.
وقال Andy Johnson، كبير مسؤولي المعلومات في شركة Real Chemistry: "نحن لا نطبق الذكاء الاصطناعي على طرق العمل القائمة بالفعل فحسب؛ بل نعيد تصور كيفية قيام فرق الخبراء في Real Chemistry بتقديم خدمات التسويق والاتصالات في مجال الرعاية الصحية. على غرار علم التشريح البشري، تم تصميم Real Chemistry ANATOMI كنظام متصل ومتطور سيستمر في التقدم جنبًا إلى جنب مع التطورات التكنولوجية واحتياجات العملاء المتغيرة، ما يتيح اتخاذ القرارات بشكل أسرع، ويضمن تنفيذًا عالي الجودة، ويوفر طرق عمل أكثر ترابطًا لتقديم نتائج مؤثرة وقابلة للقياس لعملائنا ومقدمي الخدمات والمرضى الذين يتلقون خدماتهم."
نبذة عن Real Chemistry: 25 عامًا من الرعاية الصحية التي تضع المستقبل نصب عينيها
تحتفل شركة Real Chemistry هذا العام بالذكرى السنوية الخامسة والعشرين لتأسيسها، وهي شريك تجاري من الدرجة الأولى لأكثر شركات علوم الحياة والرعاية الصحية ابتكارًا في العالم. وبصفتها مزودًا رائدًا لتحليلات الجمهور والرؤى المدعومة بالذكاء الاصطناعي، تساعد Real Chemistry قطاع الرعاية الصحية في فهم الجماهير المهمة والوصول إليها والتفاعل معها بشكل أفضل لتحسين تجربة الرعاية الصحية للجميع. وانطلاقاً من ثقافة الابتكار والإبداع، يركز أكثر من 2400 خبير عالمي في شركة Real Chemistry في مجالات علوم الحياة والتسويق والاتصالات والتكنولوجيا بشكل فريد على التغلب على تعقيدات طرح التطورات العلمية في السوق، ووضعها بين أيدي الأشخاص الذين هم في أمس الحاجة إليها. وتشمل مجموعة العلامات التجارية التابعة لشركة Real Chemistry كلاً من 21GRAMS، وهي وكالة إبداعية حائزة على جوائز عديدة، وstarpower، وهي شركة متخصصة في التعامل مع المشاهير والمؤثرين.
واليوم، تعمل Real Chemistry من خلال مكاتب في كل أنحاء أمريكا الشمالية وأوروبا والشرق الأوسط وآسيا والمحيط الهادئ، وتكملها شبكة من الشركاء الاستراتيجيين في أمريكا اللاتينية وأفريقيا، مما يمكّن الشركة من دعم العملاء أينما كان عملهم.
اعرف المزيد على www.realchemistry.com.
إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.
صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260714896757/en
الرابط الثابت
https://aetoswire.com/ar/news/1507202656270
جهات الاتصال
للتواصل الإعلامي:
media@realchemistry.com
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value
(BUSINESS WIRE)--Real Chemistry, a global leader in AI-driven insights and marketing and communications exclusively for the healthcare and life sciences sectors, today announced the launch of Real Chemistry ANATOMI, an ecosystem of AI solutions purpose-built to power the full healthcare commercialization lifecycle. The launch aligns with Real Chemistry’s 25th anniversary, marking a defining milestone in the company’s continued evolution and its commitment to staying ahead of client needs in a rapidly changing market.
Built on a foundation of advanced proprietary and third-party data, large language models (LLMs) and orchestration platforms, Real Chemistry ANATOMI integrates AI across marketing, medical affairs, communications and media workflows. From insight generation and strategy, through creative development and omnichannel activation, the ecosystem is designed to empower Real Chemistry’s experts and clients with connected, scalable, healthcare-specific AI solutions that drive measurable outcomes.
“Real Chemistry ANATOMI represents our people-first, value-driven approach to AI,” said Shankar Narayanan, Chief Executive Officer (CEO) of Real Chemistry. “For 25 years, we have evolved and invested in the talent, data, and technology required to help clients navigate increasingly complex market needs. Real Chemistry ANATOMI brings those strengths together in one all-encompassing AI ecosystem that helps our teams work smarter, move faster, and deliver more meaningful outcomes for clients, providers and patients.”
The Real Chemistry ANATOMI ecosystem delivers healthcare-specific solutions tailored to the regulatory complexity, therapeutic nuance and real-world market dynamics that shape the commercialization journey, with all authorized data ingested and stored in a highly controlled and compliant way. Real Chemistry ANATOMI combines analytics and agentic tools to support workflow-specific needs to improve quality, accelerate decision-making and enable more connected, consistent execution at scale.
Real Chemistry ANATOMI’s agentic tools were developed through thoughtful iteration and real-world validation and are already supporting core healthcare commercialization workflows:
Real Chemistry ANATOMI Communications, a curated suite customized for healthcare communications workflows, including market trends analysis, media activity reporting, reporter briefing, and executive communications planning and execution
Tooling to support end-to-end advertising and marketing workflows, from brand strategy development to cultural trends mining, and from content creation to FDA compliance risk evaluation
A bespoke set of tools to accelerate speed to insight and to enable quality in medical communications, including Real Chemistry ANATOMI Publications — an end-to-end AI-driven workflow for scientific publications planning and execution
The next-generation evolution of Real Chemistry’s HealthGEO — the industry’s first healthcare-specific GEO intelligence platform
The launch of Real Chemistry ANATOMI marks the next phase of the company’s long-standing investment in data, technology and specialized healthcare expertise, and reinforces its strategy to lead the industry in AI-enabled transformation.
As innovation accelerates across the industry, Real Chemistry remains focused on building solutions that amplify human ingenuity, connect and transform workflows, and help clients deliver stronger business and health outcomes.
“We’re not simply applying AI to existing ways of working. We’re reimagining how Real Chemistry’s expert teams deliver healthcare marketing and communications,” said Andy Johnson, Chief Information Officer (CIO) of Real Chemistry. “Like human anatomy, Real Chemistry ANATOMI is designed as a connected, evolving system that will continue to advance alongside technological advances and clients’ changing needs — enabling faster decision-making, higher-quality execution and more connected ways of working to deliver meaningful, measurable outcomes for our clients and the providers and patients they serve.”
About Real Chemistry: 25 Years of Future-Focused Healthcare
Celebrating its 25th anniversary this year, Real Chemistry is a tier-one commercialization partner to the world’s most innovative life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, Real Chemistry helps the healthcare industry better understand, reach and engage critical audiences to improve the healthcare experience for all. Anchored by a culture of innovation and creativity, Real Chemistry’s 2,400+ global experts across life sciences, marketing communications and technology are singularly focused on navigating the complexities of bringing scientific advances to market — and to the people who need them most. Real Chemistry’s brand portfolio includes 21GRAMS, a highly awarded creative agency, and starpower, a celebrity and influencer practice.
Today, Real Chemistry operates through offices across North America, Europe, the Middle East and Asia Pacific, complemented by a strategic partner network in Latin America and Africa — enabling the company to support clients wherever they operate.
Learn more at www.realchemistry.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260714896757/en/
Permalink
https://aetoswire.com/en/news/1407202656248
Contacts
Media Contact:
media@realchemistry.com
(BUSINESS WIRE)-- يسرُّ Record Asset Management GmbH (RAM)، إحدى الشركات التابعة لـ Record plc (Record Financial Group) المسجلة في لندن، أن تعلن عن إطلاق Record Amanah، وهي منصتها المخصصة للحلول الاستثمارية المتوافقة مع الشريعة.
RAM هي فرع إدارة الأصول الأوروبي من Record Financial Group، أي المجموعة الاستثمارية المتخصصة المسجلة في لندن والتي تدير 115 مليار دولار أمريكي من الأصول بالنيابة عن العملاء المؤسسيين في جميع أنحاء العالم. تشتمل قاعدة عملاء Record على صناديق التقاعد، والمؤسسات، والمؤسسات السيادية وغيرهم من مديري الأصول، والذين أسست معهم المجموعة علاقات طويلة المدى من خلال تركيزها على الاستثمار المخصص وحلول إدارة المخاطر. يقع مقر Record في لندن ولديها مكاتب في هامبورغ، وزيورخ، وتسوغ، ونيويورك وهونغ كونغ.
ويأتي الانطلاق في أعقاب معاملات ناجحة متوافقة مع الشريعة أجرتها Record مؤخرًا لأحد العملاء في بروناي، ويعكس الانطلاق الطلب المتزايد من المستثمرين المؤسسيين الذين يبحثون عن فرص استثمارية تجمع بين العوائد الجذابة المُعدلة حسب المخاطر مع الالتزام بمبادئ التمويل الإسلامي.
لقد تأسست Record Amanah بالاشتراك مع Khalij Group ( https://recordfg.com/what-we-do/private-markets/record-amanah/ )، وهم عبارة عن فريق كائن في لندن من متخصصي التمويل الإسلامي ويتمتعون بخبرة كبيرة في تنظيم الاستثمارات المتوافقة مع الشريعة وتقديم المشورة بشأنها.
ستركز المنصة في البداية على الأسواق الخاصة وفرص الملكية الخاصة، حيث توفر حلولاً استثمارية منظمة وفقًا لمبادئ الشريعة الراسخة مع الحفاظ على معايير دقة الاستثمار، وإدارة المخاطر والحوكمة التي تشتهر بها Record.
كما تعمل المبادرة على التوسع في إمكانيات الأسواق الخاصة لدى Record وتعزز قدرة المجموعة على خدمة قاعدة أكبر من المستثمرين الدوليين، وخصوصًا على مستوى الشرق الأوسط وجنوب شرق آسيا، حيثما يستمر الاحتياج إلى الحلول الاستثمارية المتوافقة مع الشريعة في الازدياد.
علّق Jan Hendrik Witte، الرئيس التنفيذي لـ Record Financial Group، قائلاً:
"يمثل إطلاق Record Amanah تطورًا طبيعيًا لإستراتيجيتنا للأسواق الخاصة. لقد أثبتنا بالفعل قدرتنا على تقديم حلول استثمارية متوافقة مع الشريعة للعملاء المؤسسيين، وتقدم هذه المنصة إطارًا مخصصًا يمكننا من خلاله التوسع في تلك الإمكانيات. ونحن نؤمن أننا مؤهلون لتلبية الاحتياج المتزايد للاستثمارات عالية الجودة المتوافقة مع الشريعة في الأسواق الخاصة وذلك بالجمع بين خبرة Record الاستثمارية، ومعرفة Khalij المتعمقة بالتمويل الإسلامي".
علّق Asim Khan، الرئيس التنفيذي لـ Khalij Group، قائلاً:
"يرتكز التمويل الإسلامي على مبادئ الشراكة، والشفافية والاستثمار في الأنشطة الاقتصادية المثمرة. ونحن نجمع هذه المبادئ مع خبرة Record في الاستثمار المؤسسي والانتشار العالمي، كل ذلك من خلال Record Amanah. ونؤمن أن هذه الشراكة ستخلق فرصًا جذابة للمستثمرين الذين يسعون لدخول الأسواق الخاصة من خلال الهياكل التي تتسم بكل من الجاذبية التجارية والتوافق الكامل مع قيم الشريعة".
يشكل الإطلاق جزءًا من إستراتيجية Record الأوسع نطاقًا المتمثلة في التوسع في أسواقها الخاصة التي توفر إمكانيات استثمارية متباينة وتخلقها للعملاء على مستوى العالم.
إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.
الرابط الثابت
https://aetoswire.com/ar/news/1307202656212
جهات الاتصال
الدكتور/ Jan Hendrik Witte
الرئيس التنفيذي
Record Financial Group
البريد الإلكتروني: reception@recordfg.com
الموقع الإلكتروني: www.recordfg.com
SAN FRANCISCO - Tuesday, 14. July 2026 AETOSWire
(BUSINESS WIRE)--Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services.
Founded in 2008 and headquartered in Turkey, ODS Consulting Group provides advisory services to organizations seeking growth, talent, and investment opportunities in Turkey and international markets. The firm supports clients through international business development and export consulting, recruitment and talent management solutions, and investment advisory services, helping businesses expand operations, access new markets, attract qualified talent, and navigate the Turkish business landscape. With a multidisciplinary approach and deep local expertise, ODS delivers tailored strategies that drive sustainable growth and long-term value creation.
“Since our founding, we have focused on helping organizations build sustainable growth through a combination of strategic insight and practical execution,” said Onur Seçkin, co-founder of ODS Consulting Group. “Working with Andersen Consulting enables us to broaden our capabilities and support clients with more integrated solutions across technology, talent, and global expansion.”
“Companies navigating transformation need solutions that extend beyond technology alone,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “ODS Consulting Group adds strength in aligning digital initiatives with workforce and operational priorities.”
Andersen Consulting is a global consulting practice providing a comprehensive suite of services spanning corporate strategy, business, technology, and AI transformation, as well as human capital solutions. Andersen Consulting integrates with the multidimensional service model of Andersen Global, delivering world-class consulting, tax, legal, valuation, global mobility, and advisory expertise on a global platform with more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms. Andersen Consulting Holdings LP is a limited partnership and provides consulting solutions through its member firms and collaborating firms around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260714843363/en/
Permalink
https://www.aetoswire.com/en/news/1407202656263
Contacts
mediainquiries@Andersen.com
SANTA MONICA, Calif. - Tuesday, 14. July 2026 AETOSWire Print
Partnership combines the Databricks platform with West Monroe's implementation expertise to help Clearlake build an “investment firm of the future” data platform across deal origination, due diligence, fund operations, and portfolio company transformation
(BUSINESS WIRE)--Clearlake Capital Group, L.P. ("Clearlake"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced a partnership with Databricks, the Data and AI company, and West Monroe, a global business and technology consulting firm, to accelerate Clearlake’s portfolio companies’ adoption of data, analytics, and AI capabilities.
Through the collaboration, Clearlake aims to connect investment, operational, financial, and portfolio data in a secure and scalable environment that accelerates enterprise-wide adoption of AI, drives productivity, and delivers measurable outcomes across the investment lifecycle from deal origination and due diligence to portfolio monitoring and value creation. By pairing cutting-edge technology with deep operational support, the partnership endeavors to help Clearlake’s portfolio companies stay ahead of industry disruption and build durable competitive advantage.
“Data and AI are increasingly becoming the core drivers of operational performance, better decision-making, and competitive advantage,” said Tony La Rosa, Managing Director, Technology and O.P.S.® at Clearlake. “This partnership brings together the Databricks platform, West Monroe's implementation expertise, and Clearlake’s O.P.S.® (Operations, People, Strategy) framework to enhance our investment process leveraging AI technologies. The partnership also aims to help our portfolio companies accelerate growth by giving management teams access to modern data infrastructure and practical AI solutions needed to improve productivity, enhance customer engagement, and create durable long-term value.”
“Investment teams in private markets are sitting on a wealth of proprietary data across deal origination, due diligence, fund operations, and portfolio company transformation, but connecting that into a coherent advantage has always been the hard part,” said Andrea DeSosa, Global Head of Capital Markets GTM at Databricks. “By partnering with Databricks and West Monroe, Clearlake is creating a stronger foundation for teams to move faster and act with more confidence, turning proprietary data into context for better decisions with the governance and controls needed to scale AI across the firm.”
“The next generation of private equity value creation will be defined by firms that can connect investment thesis, diligence insights, operational data, and AI-enabled execution,” said Keith Campbell, Global Mergers & Acquisitions and Private Equity Lead at West Monroe, a Databricks Gold Partner that helps clients build modern lakehouse and AI-ready data platforms in just weeks. “Clearlake is positioning data as an operating capability, not just a technology asset, and that mindset can create meaningful advantages from deal origination through exit.”
As part of the initiative, Clearlake also plans to bring Databricks’ capabilities to portfolio companies through its Clearlake AI Labs initiative to help management teams modernize their data infrastructure, with a focus on identifying high-impact AI use cases, building scalable data foundations, and deploying solutions that support measurable business outcomes.
About Clearlake
Clearlake Capital is a leading global alternative asset manager founded in 2006 with over $185 billion of assets under management. Clearlake offers a broad range of investment solutions across private equity, credit, infrastructure, secondaries, co-investments, and other related private market strategies. Through Pathway Capital Management, a division of Clearlake, the firm serves institutional and wealth investors seeking diversified access to private markets. Clearlake seeks to partner with experienced management teams by providing patient, long-term capital to businesses across multiple sectors. The firm aims to drive value through its active, hands-on operating approach, O.P.S.® (Operations, People, Strategy), which combines deep operational expertise with strategic and talent-focused initiatives. Headquartered in Santa Monica, Clearlake maintains 14 offices across the Americas, Europe, Asia, and the Middle East. For more information, please visit clearlake.com or follow us on LinkedIn.
About West Monroe
West Monroe is an AI-native global consulting firm built for today’s pace of change. We combine deep industry expertise with modern technology and business transformation capabilities to help organizations move faster, create value, and deliver measurable impact. We don’t just talk about what’s possible—we apply AI and technology where it matters most, pairing strategic insights with hands-on execution to help clients move from strategy to results, faster.
Clients tell us we show up differently. Our employee ownership model fuels an all-in approach grounded in practical execution, measurable impact, and lasting partnership. That commitment has earned recognition from Forbes and Business Insider and made West Monroe one of only 22 companies recognized worldwide for building high-quality careers. See what’s possible at westmonroe.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260714925130/en/
Permalink
https://www.aetoswire.com/en/news/1407202656264
Contacts
Media Contacts:
For Clearlake
Tasha Pelio
Tasha.pelio@clearlake.com
310-400-8879
For West Monroe
Christina Galoozis
Director, External Communications
cgaloozis@westmonroe.com
847-302-1762
There are currently no blog comments.